Issue: May 2017
Source:

Höhn R, et al. Br J Ophthalmol. 2017;doi:10.1136/bjophthalmol-2016-309993.

May 03, 2017
1 min read
Save

Systemic beta-blockers have ‘negligible’ effect on IOP reduction

Issue: May 2017
Source:

Höhn R, et al. Br J Ophthalmol. 2017;doi:10.1136/bjophthalmol-2016-309993.

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Non-glaucoma subjects who take selective or non-selective systemic beta-blockers did not experience significantly lowered IOP, according to a study.

Researchers evaluated the IOP of 13,527 non-glaucoma subjects in the Gutenberg Health Study, a population-based, prospective, observational cohort study in Germany. Several cardiovascular medications, including beta-blockers, calcium channel blockers, renin-angiotensin blockers and other medications, were evaluated, and IOP was measured with a non-contact tonometer.

The overall mean IOP for the cohort was 14.2 mm Hg.

There was no association between statistically significant lower IOP and the use of selective or non-selective beta-blockers.

In a multivariable linear regression model, ACE inhibitors and renin-angiotensin blockers in general showed an association with IOP, but after adjusting for BMI, systolic blood pressure and central corneal thickness, no associations were seen.

“While non-selective systemic -blocker intake showed a clinically relevant association and a borderline significant trend with IOP decrease, the use of the widespread modern cardio-selective -blockers and all other cardiovascular medication did not. The missing IOP-lowering effect of systemic -blocker might be explained by the long-term drift, which describes a well-known reduction in efficacy of topical -blocker over months and years. ... Our results suggest that systemic -blockers have — if at all — a negligible effect on IOP reduction,” the study authors wrote. – by Robert Linnehan

Disclosures: The authors report no relevant financial disclosures.